Shots:

• mAbxience will produce ~200M + doses of AZD1222 and will supply it to all Latin American countries- except Brazil
• The company will produce API in its facility located in Garín (Argentina) and will send it to Mexico to complete the production and filling process. AstraZeneca will transfer its technology to the Garín plant shortly- allowing the facility to produce the vaccine in the coming months
• AstraZeneca’s AZD1222 has demonstrated robust immune response in its P-I & II studies- being evaluated in P-III study with its expected completion in the coming months. The vaccine is expected to be available in the H1’21- upon completion of the P-III trial and approval

 Ref: mAbxience | Image: Thailand Medical News 

Click here ­to­ read full press release/ article